ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 355,37
1,00%
Dow Jones
42 992,21
-0,77%
DAX
19 984,32
0,74%
Brent Oil
73,775
0,20%
Bitcoin
93 707,28
0,20%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. MaxCyte Inc (MXCT)

  7. MaxCyte Inc (MXCT) Actualités

MXCT

MaxCyte (MXCT)

MaxCyte Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MXCT
DateHeureSourceTitreSymboleSociété
27/12/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MXCTMaxCyte Inc
26/12/202422h16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MXCTMaxCyte Inc
23/12/202408h00GlobeNewswire Inc.MaxCyte Announces Retirement of Board Member Art MandellNASDAQ:MXCTMaxCyte Inc
10/12/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MXCTMaxCyte Inc
09/12/202408h00GlobeNewswire Inc.MaxCyte Announces Streamlined Operations and Raises 2024 Revenue GuidanceNASDAQ:MXCTMaxCyte Inc
14/11/202401h14Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MXCTMaxCyte Inc
13/11/202414h05GlobeNewswire Inc.MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based TherapeuticsNASDAQ:MXCTMaxCyte Inc
06/11/202422h55Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MXCTMaxCyte Inc
06/11/202422h05GlobeNewswire Inc.MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 GuidanceNASDAQ:MXCTMaxCyte Inc
31/10/202413h05GlobeNewswire Inc.MaxCyte to Participate in Two Upcoming Investor ConferencesNASDAQ:MXCTMaxCyte Inc
16/10/202423h32Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MXCTMaxCyte Inc
15/10/202414h05GlobeNewswire Inc.MaxCyte Appoints Cynthia Collins to its Board of DirectorsNASDAQ:MXCTMaxCyte Inc
11/10/202414h05GlobeNewswire Inc.MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024NASDAQ:MXCTMaxCyte Inc
10/10/202414h05GlobeNewswire Inc.MaxCyte Appoints Ali Soleymannezhad as Chief Commercial OfficerNASDAQ:MXCTMaxCyte Inc
16/09/202408h00GlobeNewswire Inc.MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic DiseasesNASDAQ:MXCTMaxCyte Inc
05/09/202422h05GlobeNewswire Inc.MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing ConferenceNASDAQ:MXCTMaxCyte Inc
06/08/202422h05GlobeNewswire Inc.MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 GuidanceNASDAQ:MXCTMaxCyte Inc
09/07/202422h05GlobeNewswire Inc.MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024NASDAQ:MXCTMaxCyte Inc
29/05/202414h05GlobeNewswire Inc.MaxCyte to Participate in William Blair 44th Annual Growth Stock ConferenceNASDAQ:MXCTMaxCyte Inc
22/05/202414h05GlobeNewswire Inc.MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and DevelopmentNASDAQ:MXCTMaxCyte Inc
07/05/202422h05GlobeNewswire Inc.MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 GuidanceNASDAQ:MXCTMaxCyte Inc
10/04/202414h05GlobeNewswire Inc.MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024NASDAQ:MXCTMaxCyte Inc
02/04/202414h05GlobeNewswire Inc.MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)NASDAQ:MXCTMaxCyte Inc
12/03/202421h05GlobeNewswire Inc.MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceNASDAQ:MXCTMaxCyte Inc
04/03/202422h05GlobeNewswire Inc.MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsNASDAQ:MXCTMaxCyte Inc
14/02/202422h26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MXCTMaxCyte Inc
14/02/202418h25Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MXCTMaxCyte Inc
09/02/202414h05GlobeNewswire Inc.MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor ConferencesNASDAQ:MXCTMaxCyte Inc
30/01/202414h05GlobeNewswire Inc.MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for CancersNASDAQ:MXCTMaxCyte Inc
23/01/202414h05GlobeNewswire Inc.MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy ProgramsNASDAQ:MXCTMaxCyte Inc
 Showing the most relevant articles for your search:NASDAQ:MXCT

Dernières Valeurs Consultées

BIT
ADV
Adventure
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés